Ulcerative Colitis and Acute Severe Ulcerative Colitis Patients Are Overlooked in Infliximab Population Pharmacokinetic Models: Results from a Comprehensive Review

Ulcerative colitis (UC) is part of the inflammatory bowels diseases, and moderate to severe UC patients can be treated with anti-tumour necrosis α monoclonal antibodies, including infliximab (IFX). Even though treatment of UC patients by IFX has been in place for over a decade, many gaps in modellin...

Full beskrivning

Bibliografiska uppgifter

Huvudupphov:	Alix Démaris, Ella S. K. Widigson, Johan F. K. F. Ilvemark, Casper Steenholdt, Jakob B. Seidelin, Wilhelm Huisinga, Robin Michelet, Linda B. S. Aulin, Charlotte Kloft
Materialtyp:	Artigo
Språk:	Inglês
Utgiven:	MDPI AG 2022-09-01
Serie:	Pharmaceutics
Ämnen:	infliximab inflammatory bowel disease ulcerative colitis acute severe ulcerative colitis disease activity
Länkar:	https://www.mdpi.com/1999-4923/14/10/2095
Taggar:	Lägg till en tagg Inga taggar, Lägg till första taggen!